Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Buy
52
QGEN Quote, Financials, Valuation and Earnings
Last price:
$45.61
Seasonality move
:
7.55%
Day range:
$45.60 - $46.17
52-week range:
$37.63 - $51.88
Dividend yield:
0.55%
P/E ratio:
24.60x
P/S ratio:
4.82x
P/B ratio:
2.71x
Volume:
1M
Avg. volume:
1.2M
1-year change:
-1.06%
Market cap:
$9.9B
Revenue:
$2B
EPS (TTM):
$1.85
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
QGEN
QIAGEN NV
|
$525.7M | $0.59 | 1.41% | 47.09% | $50.57 |
|
CDT
CDT Equity, Inc.
|
-- | -- | -- | -- | -- |
|
IFRX
InflaRx NV
|
$34.6K | -$0.14 | -74.55% | -16.09% | $11.24 |
|
LENZ
LENZ Therapeutics, Inc.
|
$4.6M | -$0.69 | -7.14% | -109.39% | $53.71 |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | -- |
|
ORKA
Oruka Therapeutics, Inc.
|
-- | -$0.52 | -- | -1.78% | $49.45 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
QGEN
QIAGEN NV
|
$45.61 | $50.57 | $9.9B | 24.60x | $0.25 | 0.55% | 4.82x |
|
CDT
CDT Equity, Inc.
|
$1.59 | -- | $2.6M | -- | $0.00 | 0% | -- |
|
IFRX
InflaRx NV
|
$1.08 | $11.24 | $73.2M | -- | $0.00 | 0% | 333.70x |
|
LENZ
LENZ Therapeutics, Inc.
|
$16.89 | $53.71 | $528.5M | -- | $1.03 | 0% | 26.94x |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
ORKA
Oruka Therapeutics, Inc.
|
$31.71 | $49.45 | $1.5B | -- | $19.36 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
QGEN
QIAGEN NV
|
36.82% | 0.236 | 21.96% | 2.12x |
|
CDT
CDT Equity, Inc.
|
30.47% | -0.945 | 27% | 1.13x |
|
IFRX
InflaRx NV
|
2.1% | -0.453 | 1.26% | 2.34x |
|
LENZ
LENZ Therapeutics, Inc.
|
0.49% | -0.080 | 0.07% | 12.39x |
|
LIMN
Liminatus Pharma
|
-- | 0.000 | -- | -- |
|
ORKA
Oruka Therapeutics, Inc.
|
0.39% | 1.816 | 0.2% | 16.65x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
QGEN
QIAGEN NV
|
$329.1M | $137.3M | 7.77% | 11.48% | 25.78% | $114.6M |
|
CDT
CDT Equity, Inc.
|
-$885K | -$7M | -898.82% | -- | -- | -$4.4M |
|
IFRX
InflaRx NV
|
-$89.2K | -$11.7M | -80.95% | -82.01% | -42057.91% | -$11.4M |
|
LENZ
LENZ Therapeutics, Inc.
|
$12.4M | -$18.9M | -28.93% | -29.1% | -151.1% | -$9M |
|
LIMN
Liminatus Pharma
|
-- | -- | -- | -- | -- | -- |
|
ORKA
Oruka Therapeutics, Inc.
|
-$20K | -$34.1M | -25.67% | -25.76% | -- | -$21.7M |
QIAGEN NV vs. Competitors
-
Which has Higher Returns QGEN or CDT?
CDT Equity, Inc. has a net margin of 24.42% compared to QIAGEN NV's net margin of --. QIAGEN NV's return on equity of 11.48% beat CDT Equity, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital QGENQIAGEN NV61.8% $0.60 $5.8B CDTCDT Equity, Inc.-- -$13.16 $6.2M -
What do Analysts Say About QGEN or CDT?
QIAGEN NV has a consensus price target of $50.57, signalling upside risk potential of 10.88%. On the other hand CDT Equity, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that QIAGEN NV has higher upside potential than CDT Equity, Inc., analysts believe QIAGEN NV is more attractive than CDT Equity, Inc..
Company Buy Ratings Hold Ratings Sell Ratings QGENQIAGEN NV3 10 0 CDTCDT Equity, Inc.0 0 0 -
Is QGEN or CDT More Risky?
QIAGEN NV has a beta of 0.680, which suggesting that the stock is 32.001% less volatile than S&P 500. In comparison CDT Equity, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock QGEN or CDT?
QIAGEN NV has a quarterly dividend of $0.25 per share corresponding to a yield of 0.55%. CDT Equity, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. QIAGEN NV pays -- of its earnings as a dividend. CDT Equity, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QGEN or CDT?
QIAGEN NV quarterly revenues are $532.6M, which are larger than CDT Equity, Inc. quarterly revenues of --. QIAGEN NV's net income of $130M is higher than CDT Equity, Inc.'s net income of -$7.1M. Notably, QIAGEN NV's price-to-earnings ratio is 24.60x while CDT Equity, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QIAGEN NV is 4.82x versus -- for CDT Equity, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QGENQIAGEN NV4.82x 24.60x $532.6M $130M CDTCDT Equity, Inc.-- -- -- -$7.1M
-
Which has Higher Returns QGEN or IFRX?
InflaRx NV has a net margin of 24.42% compared to QIAGEN NV's net margin of -51538.49%. QIAGEN NV's return on equity of 11.48% beat InflaRx NV's return on equity of -82.01%.
Company Gross Margin Earnings Per Share Invested Capital QGENQIAGEN NV61.8% $0.60 $5.8B IFRXInflaRx NV-320.86% -$0.21 $54.4M -
What do Analysts Say About QGEN or IFRX?
QIAGEN NV has a consensus price target of $50.57, signalling upside risk potential of 10.88%. On the other hand InflaRx NV has an analysts' consensus of $11.24 which suggests that it could grow by 941.09%. Given that InflaRx NV has higher upside potential than QIAGEN NV, analysts believe InflaRx NV is more attractive than QIAGEN NV.
Company Buy Ratings Hold Ratings Sell Ratings QGENQIAGEN NV3 10 0 IFRXInflaRx NV5 2 0 -
Is QGEN or IFRX More Risky?
QIAGEN NV has a beta of 0.680, which suggesting that the stock is 32.001% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.459, suggesting its more volatile than the S&P 500 by 45.896%.
-
Which is a Better Dividend Stock QGEN or IFRX?
QIAGEN NV has a quarterly dividend of $0.25 per share corresponding to a yield of 0.55%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. QIAGEN NV pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QGEN or IFRX?
QIAGEN NV quarterly revenues are $532.6M, which are larger than InflaRx NV quarterly revenues of $27.8K. QIAGEN NV's net income of $130M is higher than InflaRx NV's net income of -$14.3M. Notably, QIAGEN NV's price-to-earnings ratio is 24.60x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QIAGEN NV is 4.82x versus 333.70x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QGENQIAGEN NV4.82x 24.60x $532.6M $130M IFRXInflaRx NV333.70x -- $27.8K -$14.3M
-
Which has Higher Returns QGEN or LENZ?
LENZ Therapeutics, Inc. has a net margin of 24.42% compared to QIAGEN NV's net margin of -133.6%. QIAGEN NV's return on equity of 11.48% beat LENZ Therapeutics, Inc.'s return on equity of -29.1%.
Company Gross Margin Earnings Per Share Invested Capital QGENQIAGEN NV61.8% $0.60 $5.8B LENZLENZ Therapeutics, Inc.99% -$0.59 $194.9M -
What do Analysts Say About QGEN or LENZ?
QIAGEN NV has a consensus price target of $50.57, signalling upside risk potential of 10.88%. On the other hand LENZ Therapeutics, Inc. has an analysts' consensus of $53.71 which suggests that it could grow by 218.02%. Given that LENZ Therapeutics, Inc. has higher upside potential than QIAGEN NV, analysts believe LENZ Therapeutics, Inc. is more attractive than QIAGEN NV.
Company Buy Ratings Hold Ratings Sell Ratings QGENQIAGEN NV3 10 0 LENZLENZ Therapeutics, Inc.6 0 0 -
Is QGEN or LENZ More Risky?
QIAGEN NV has a beta of 0.680, which suggesting that the stock is 32.001% less volatile than S&P 500. In comparison LENZ Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock QGEN or LENZ?
QIAGEN NV has a quarterly dividend of $0.25 per share corresponding to a yield of 0.55%. LENZ Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $1.03 per share. QIAGEN NV pays -- of its earnings as a dividend. LENZ Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QGEN or LENZ?
QIAGEN NV quarterly revenues are $532.6M, which are larger than LENZ Therapeutics, Inc. quarterly revenues of $12.5M. QIAGEN NV's net income of $130M is higher than LENZ Therapeutics, Inc.'s net income of -$16.7M. Notably, QIAGEN NV's price-to-earnings ratio is 24.60x while LENZ Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QIAGEN NV is 4.82x versus 26.94x for LENZ Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QGENQIAGEN NV4.82x 24.60x $532.6M $130M LENZLENZ Therapeutics, Inc.26.94x -- $12.5M -$16.7M
-
Which has Higher Returns QGEN or LIMN?
Liminatus Pharma has a net margin of 24.42% compared to QIAGEN NV's net margin of --. QIAGEN NV's return on equity of 11.48% beat Liminatus Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital QGENQIAGEN NV61.8% $0.60 $5.8B LIMNLiminatus Pharma-- -- -- -
What do Analysts Say About QGEN or LIMN?
QIAGEN NV has a consensus price target of $50.57, signalling upside risk potential of 10.88%. On the other hand Liminatus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that QIAGEN NV has higher upside potential than Liminatus Pharma, analysts believe QIAGEN NV is more attractive than Liminatus Pharma.
Company Buy Ratings Hold Ratings Sell Ratings QGENQIAGEN NV3 10 0 LIMNLiminatus Pharma0 0 0 -
Is QGEN or LIMN More Risky?
QIAGEN NV has a beta of 0.680, which suggesting that the stock is 32.001% less volatile than S&P 500. In comparison Liminatus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock QGEN or LIMN?
QIAGEN NV has a quarterly dividend of $0.25 per share corresponding to a yield of 0.55%. Liminatus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. QIAGEN NV pays -- of its earnings as a dividend. Liminatus Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QGEN or LIMN?
QIAGEN NV quarterly revenues are $532.6M, which are larger than Liminatus Pharma quarterly revenues of --. QIAGEN NV's net income of $130M is higher than Liminatus Pharma's net income of --. Notably, QIAGEN NV's price-to-earnings ratio is 24.60x while Liminatus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QIAGEN NV is 4.82x versus -- for Liminatus Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QGENQIAGEN NV4.82x 24.60x $532.6M $130M LIMNLiminatus Pharma-- -- -- --
-
Which has Higher Returns QGEN or ORKA?
Oruka Therapeutics, Inc. has a net margin of 24.42% compared to QIAGEN NV's net margin of --. QIAGEN NV's return on equity of 11.48% beat Oruka Therapeutics, Inc.'s return on equity of -25.76%.
Company Gross Margin Earnings Per Share Invested Capital QGENQIAGEN NV61.8% $0.60 $5.8B ORKAOruka Therapeutics, Inc.-- -$0.69 $488.7M -
What do Analysts Say About QGEN or ORKA?
QIAGEN NV has a consensus price target of $50.57, signalling upside risk potential of 10.88%. On the other hand Oruka Therapeutics, Inc. has an analysts' consensus of $49.45 which suggests that it could grow by 55.96%. Given that Oruka Therapeutics, Inc. has higher upside potential than QIAGEN NV, analysts believe Oruka Therapeutics, Inc. is more attractive than QIAGEN NV.
Company Buy Ratings Hold Ratings Sell Ratings QGENQIAGEN NV3 10 0 ORKAOruka Therapeutics, Inc.10 0 0 -
Is QGEN or ORKA More Risky?
QIAGEN NV has a beta of 0.680, which suggesting that the stock is 32.001% less volatile than S&P 500. In comparison Oruka Therapeutics, Inc. has a beta of -0.409, suggesting its less volatile than the S&P 500 by 140.861%.
-
Which is a Better Dividend Stock QGEN or ORKA?
QIAGEN NV has a quarterly dividend of $0.25 per share corresponding to a yield of 0.55%. Oruka Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $19.36 per share. QIAGEN NV pays -- of its earnings as a dividend. Oruka Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QGEN or ORKA?
QIAGEN NV quarterly revenues are $532.6M, which are larger than Oruka Therapeutics, Inc. quarterly revenues of --. QIAGEN NV's net income of $130M is higher than Oruka Therapeutics, Inc.'s net income of -$30.3M. Notably, QIAGEN NV's price-to-earnings ratio is 24.60x while Oruka Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QIAGEN NV is 4.82x versus -- for Oruka Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QGENQIAGEN NV4.82x 24.60x $532.6M $130M ORKAOruka Therapeutics, Inc.-- -- -- -$30.3M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 3.95% over the past day.
Buy
85
HUT alert for Dec 24
Hut 8 Corp. [HUT] is up 4.13% over the past day.
Buy
63
GPCR alert for Dec 24
Structure Therapeutics, Inc. [GPCR] is up 12.87% over the past day.
